The combination of VEGFR-2 inhibitors with PD-1 immunotherapy has been shown to enhance effective blood perfusion, alleviate hypoxia, promote infiltration of CD8a+ T lymphocytes into the tumor, and exert synergistic anti-tumor effects on the mouse colon cancer model. This evidence concerns the gene KDR and colonic neoplasm.